H eart transplantation remains the only definitive treatment for end-stage heart failure. Advances in immunosuppressive therapies have improved outcomes; however, allograft rejection is still a major impediment to survival. Although cellular rejection rates have been declining, rates of antibody-mediated rejection (AMR) have shown little improvement and afflict 10% to 20% of patients. 1 AMR correlates with adverse outcomes, including hemodynamic compromise rejection, cardiac allograft vasculopathy, and death. 1 Despite efforts from the International Society of Heart and Lung Transplantation (ISHLT) to standardize the diagnosis and grading of AMR, 2 subjectivity in interpreting histological findings will continue to be an insurmountable obstacle. This is not helped by a limited understanding of the pathophysiology of the disease. 2 In this issue of Circulation, Loupy et al 3 address this knowledge gap by using gene expression profiling in endomyocardial biopsy (EMB) samples from heart transplant recipients with AMR. Gene expression profiling of allograft biopsy samples using RNA extraction and microarray analysis was performed on 71 biopsy samples from 55 patients who were diagnosed with AMR using conventional histology. They were compared with a matched control group of 55 rejection-free and acute cellular rejection (ACR) patients to eliminate any overlap in gene expression between the 2 types of rejection. AMR was diagnosed by using the 2013 ISHLT pathological grading system (Table) , and patients with all grades were included. This study is the first to characterize the molecular landscape of AMR in heart transplantation by using EMB samples. The results showed that 4 gene sets are expressed in AMR and include natural killer cell activation, macrophage activation, endothelial cells, and interferon-gamma responses. Expression of these genes correlates with the 2013 ISHLT pathological grading of AMR. Microarray analysis goes beyond the current scheme to provide increased resolution within histological AMR grades. For instance, pAMR1 (I+) is less transcriptionally active than pAMR1 (H+), which is as active as pAMR2/3. There is also evidence to suggest that pAMR1 (H+) is associated with accelerated cardiac allograft vasculopathy. 5 This is clinically significant given that most transplant clinicians only treat grade 2 and above.
Earlier work by Halloran et al 6 characterized the molecular state of AMR, ACR, and acute kidney injury in biopsy samples from renal transplant recipients. The lack of C4d deposits in many kidney allograft AMR cases precipitated the need for a more accurate test. To provide more granularity to AMR diagnosis, Loupy and colleagues 3 have used microarray analysis and phenotyping by analyzing messenger RNA in tissue samples. Messenger RNA was chosen because it can be amplified easily, whereas proteins and metabolites associated with disease states are in low abundance and therefore difficult to detect. For testing purposes, a biopsy sample is suspended in reagent that hybridizes to tagged probes on a gene chip microarray.
The results from molecular analysis are compared with a reference set, and machine-learning algorithms determine the probability of disease in the sample. Having the potential to identify disease states, microarray analysis can define the molecular landscape in disease states, as well, to help refine the understanding of the underlying pathophysiology. Indeed, the work by Loupy has helped toward a better understanding of the mechanisms of AMR in heart transplantation.
Although the EMB is the clinical standard for monitoring and guiding treatment of allograft rejection in cardiac transplantation, it is neither ideal nor a true gold standard. Histological grading systems are subjective and change frequently. One of the hallmarks of a gold standard diagnostic test is reproducibility. The CARGO II study (Cardiac Allograft Rejection Gene Expression Observational II Study) 7 evaluated concordance among pathologists using the 2004 ISHLT grading system for ACR. A panel of 4 independent pathologists assessed EMB samples from participating study centers that had been graded by the local pathologist. Although agreement between local and panel pathologists was 71% overall, samples assigned grade ≥2R (threshold to treat ACR) had a concordance rate of only 28.4%. 7 In 19.2% of samples graded ≥2R by local pathologists, the panel was unable to reach a majority agreement. 7 The reproducibility of AMR pathology reads on EMB may be even worse, because there appears to be more subjectivity in reading AMR histology.
Previous work on gene expression profiling of peripheral blood sought to improve the process of allograft surveillance in stable patients. 8 In contrast, Loupy et al 3 seek to enrich the pathophysiologic understanding of rejection, and endeavor to pave the way to a gold standard. Further research should focus on refining molecular analysis as a diagnostic tool. This will be achieved by refining reference sets through accurate phenotyping of biopsy samples. Noninvasive biomarkers can then be refined according to the true pathological picture by using molecular analysis as a benchmark rather than subjective histology readings. Although promising, the study by Loupy et al 3 needs further validation on unselected patients prospectively. There are also practical questions that need to be addressed such as how scar tissue or infection affects results, how much EMB material is needed for a valid result, and whether cardiac hemodynamics play a role.
Genomic medicine is gradually making its way into heart transplantation. Other approaches under investigation include gene expression profiling of peripheral blood, donor-derived cell-free DNA, and micro-RNA. Gene expression profiling of peripheral blood with the AllopMap test (CareDX) is in current clinical use and incorporated into the ISHLT guidelines. The landmark IM-AGE trial (Invasive Monitoring Attenuation through Gene Expression) 8 was a noninferiority trial comparing AlloMap with EMB. The study randomly assigned 602 patients who had undergone heart transplantation to either EMB or AlloMap surveillance for ACR. Outcomes, including mortality, were similar between the 2 groups. Patients in the AlloMap arm underwent fewer biopsies, and patient satisfaction was higher. Of interest, there were episodes where a negative biopsy read by the local pathologist was upgraded to 2R rejection by the pathology core laboratory. The patients from whom these EMBs were taken were not treated because the local pathology read was used to manage therapy. Given that survival was similar between the 2 groups, this pathology core-read 2R rejection may reflect an incorrect diagnosis of 2R rejection or may represent asymptomatic rejection that is not clinically relevant. Another genomic tool is the use of donor-derived cell-free DNA that takes advantage of the differences between the recipient's and the donor's genome. This modality works on the notion that damage to the allograft will result in donor DNA spilling over into the recipient's serum. A small number of pilot studies [9] [10] [11] show potential for donor-derived cell-free DNA in monitoring for rejection before the onset of symptoms. Last, micro-RNAs serve as posttranscription regulators. They bind to and degrade messenger RNA. Some micro- RNAs are stable and detectable in plasma. They too may serve as a biomarker for rejection. 12 When evaluating novel tests such as those mentioned above, a lack of reproducibility in pathology reads of rejection makes it difficult to determine whether the novel test truly identifies EMB rejection.
In conclusion, there is an unmet need in transplantation to create an objective diagnostic test for allograft rejection. The pathology reads of EMB-proven rejection are not consistent, possibly because of histology errors, sampling errors, or even imprecise definitions of ACR/ AMR. Loupy's work 3 suggests that gene expression profiling of allograft EMB samples by using RNA extraction and microarray analysis provides a much-needed objective method for defining true pathology states of rejection. Indeed, we may be closer to a true gold standard to detect rejection.
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